Trials / Unknown
UnknownNCT05794477
A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 132 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Adebrelimab | Specified dose on specified days |
| BIOLOGICAL | SHR-1802 | Specified dose on specified days |
| DRUG | Carboplatin/Cisplatin | Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy. |
| DRUG | Paclitaxel/Nab-Paclitaxel/Pemetrexed | Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy. |
Timeline
- Start date
- 2023-04-28
- Primary completion
- 2025-07-01
- Completion
- 2025-12-31
- First posted
- 2023-04-03
- Last updated
- 2023-06-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05794477. Inclusion in this directory is not an endorsement.